Page 266 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 14 Cancer Immunotherapy 245

80. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A: suppressor cells in cancer is regulated by S100A9 protein, J Exp
CD4+CD25+ regulatory T cells in patients with gastrointestinal Med 205(10):2235–2249, 2008.
malignancies: possible involvement of regulatory T cells in disease 101. Herber DL, Cao W, Nefedova Y, et al.: Lipid accumulation and
VetBooks.ir 81. Turk MJ, Guevara-Patino JA, Rizzuto GA, et al.: Concomitant dendritic cell dysfunction in cancer, Nat Med 16(8):880–886,
progression, Cancer 98(5):1089–1099, 2003.
2010.
tumor immunity to a poorly immunogenic melanoma is prevented
and functional analysis of tumor-infiltrating plasmacytoid den-
by regulatory T cells, J Exp Med 200(6):771–782, 2004. 102. Hartmann E, Wollenberg B, Rothenfusser S, et al.: Identification
82. Viguier M, Lemaitre F, Verola O, et al.: Foxp3 expressing dritic cells in head and neck cancer, Cancer Res 63(19):6478–6487,
CD4+CD25(high) regulatory T cells are overrepresented in human 2003.
metastatic melanoma lymph nodes and inhibit the function of 103. Gerlini G, Tun-Kyi A, Dudli C, et al.: Metastatic melanoma
infiltrating T cells, J Immunol 173(2):1444–1453, 2004. secreted IL-10 down-regulates CD1 molecules on dendritic cells in
83. Biller BJ, Elmslie RE, Burnett RC, et al.: Use of FoxP3 expression metastatic tumor lesions, Am J Pathol 165(6):1853–1863, 2004.
to identify regulatory T cells in healthy dogs and dogs with cancer, 104. Gabrilovich DI, Chen HL, Girgis KR, et al.: Production of vascular
Vet Immunol Immunopathol 116(1-2):69–78, 2007. endothelial growth factor by human tumors inhibits the functional
84. Teng MW, Swann JB, von Scheidt B, et al.: Multiple antitumor maturation of dendritic cells, Nat Med 2(10):1096–1103, 1996.
mechanisms downstream of prophylactic regulatory T-cell deple- 105. Zhang M, Tang H, Guo Z, et al.: Splenic stroma drives mature
tion, Cancer Res 70(7):2665–2674, 2010. dendritic cells to differentiate into regulatory dendritic cells, Nat
85. Piconese S, Valzasina B, Colombo MP: OX40 triggering blocks Immunol 5(11):1124–1133, 2004.
suppression by regulatory T cells and facilitates tumor rejection, 106. Lin WW, Karin M: A cytokine-mediated link between innate
J Exp Med 205(4):825–839, 2008. immunity, inflammation, and cancer, J Clin Invest 117(5):1175–
86. Berraondo P, Nouze C, Preville X, et al.: Eradication of large 1183, 2007.
tumors in mice by a tritherapy targeting the innate, adaptive, 107. Ridge J, Terle DA, Dragunsky E, Levenbook I: Effects of gamma-
and regulatory components of the immune system, Cancer Res IFN and NGF on subpopulations in a human neuroblastoma cell
67(18):8847–8855, 2007. line: flow cytometric and morphologic analysis, Vitro Cell Dev Biol
87. Matar P, Rozados VR, Gonzalez AD, et al.: Mechanism of anti- Anim 32(4):238–248, 1996.
metastatic immunopotentiation by low-dose cyclophosphamide, 108. Maloy KJ, Salaun L, Cahill R, et al.: CD4+CD25+ T(R) cells
Eur J Cancer 36(8):1060–1066, 2000. suppress innate immune pathology through cytokine-dependent
88. Ghiringhelli F, Menard C, Puig PE, et al.: Metronomic cyclo- mechanisms, J Exp Med 197(1):111–119, 2003.
phosphamide regimen selectively depletes CD4+CD25+ regula- 109. Sredni B, Weil M, Khomenok G, et al.: Ammonium tric-
tory T cells and restores T and NK effector functions in end stage hloro(dioxoethylene-o,o’)tellurate (AS101) sensitizes tumors to
cancer patients, Cancer immunol immunother CII 56(5):641–648, chemotherapy by inhibiting the tumor interleukin 10 autocrine
2007. loop, Cancer Res 64(5):1843–1852, 2004.
89. Mitchell L, Thamm DH, Biller BJ: Clinical and immunomodula- 110. Ebrahimi B, Tucker SL, Li D, et al.: Cytokines in pancreatic car-
tory effects of toceranib combined with low-dose cyclophospha- cinoma: correlation with phenotypic characteristics and prognosis,
mide in dogs with cancer, J Vet Intern Med 26(2):355–362, 2012. Cancer 101(12):2727–2736, 2004.
90. Hoffmann TK, Muller-Berghaus J, Ferris RL, et al.: Alterations in 111. Ozdemir F, Aydin F, Yilmaz M, et al.: The effects of IL-2, IL-6
the frequency of dendritic cell subsets in the peripheral circulation and IL-10 levels on prognosis in patients with aggressive non-
of patients with squamous cell carcinomas of the head and neck, Hodgkin’s lymphoma (NHL), J Exp Clin Cancer Res 23(3):485–
Clin Cancer Res 8(6):1787–1793, 2002. 488, 2004.
91. Pinzon-Charry A, Ho CS, Laherty R, et al.: A population of 112. Lech-Maranda E, Bienvenu J, Michallet AS, et al.: Elevated IL-10
HLA-DR+ immature cells accumulates in the blood dendritic cell plasma levels correlate with poor prognosis in diffuse large B-cell
compartment of patients with different types of cancer, Neoplasia lymphoma, Eur Cytokine Netw 17(1):60–66, 2006.
7(12):1112–1122, 2005. 113. Becker C, Fantini MC, Neurath MF: TGF-beta as a T cell regula-
92. Steinman RM, Hawiger D, Nussenzweig MC: Tolerogenic den- tor in colitis and colon cancer, Cytokine Growth Factor Rev 17(1-2):
dritic cells, Annu Rev Immunol 21:685–711, 2003. 97–106, 2006.
93. Fuchs EJ, Matzinger P: Is cancer dangerous to the immune system? 114. Ghiringhelli F, Puig PE, Roux S, et al.: Tumor cells convert imma-
Semin Immunol 8(5):271–280, 1996. ture myeloid dendritic cells into TGF-beta-secreting cells induc-
94. Enk AH, Jonuleit H, Saloga J, Knop J: Dendritic cells as mediators ing CD4+CD25+ regulatory T cell proliferation, J Exp Med
of tumor-induced tolerance in metastatic melanoma, Int J Cancer 202(7):919–929, 2005.
73(3):309–316, 1997. 115. Derynck R, Akhurst RJ, Balmain A: TGF-beta signaling in tumor
95. Nestle FO, Burg G, Fah J, et al.: Human sunlight-induced basal- suppression and cancer progression, Nat Genet 29(2):117–129,
cell-carcinoma-associated dendritic cells are deficient in T cell co- 2001.
stimulatory molecules and are impaired as antigen-presenting cells, 116. Luo JL, Maeda S, Hsu LC, et al.: Inhibition of NF-kappaB in
Am J Pathol 150(2):641–651, 1997. cancer cells converts inflammation- induced tumor growth medi-
96. Chaux P, Favre N, Martin M, Martin F: Tumor-infiltrating den- ated by TNFalpha to TRAIL-mediated tumor regression, Cancer
dritic cells are defective in their antigen-presenting function and Cell 6(3):297–305, 2004.
inducible B7 expression in rats, Int J Cancer 72(4):619–624, 1997. 117. Elgert KD, Alleva DG, Mullins DW: Tumor-induced immune
97. Ishida T, Oyama T, Carbone DP, Gabrilovich DI: Defective func- dysfunction: the macrophage connection, J Leukoc Biol 64(3):275–
tion of Langerhans cells in tumor-bearing animals is the result of 290, 1998.
defective maturation from hemopoietic progenitors, J Immunol 118. Catchpole B, Gould SM, Kellett-Gregory LM, Dobson JM:
161(9):4842–4851, 1998. Immunosuppressive cytokines in the regional lymph node of a
98. Almand B, Resser JR, Lindman B, et al.: Clinical significance of dog suffering from oral malignant melanoma, J Small Anim Pract
defective dendritic cell differentiation in cancer, Clin Cancer Res 43(10):464–467, 2002.
6(5):1755–1766, 2000. 119. Richardson MA, Ramirez T, Russell NC, Moye LA: Coley toxins
99. Troy AJ, Summers KL, Davidson PJ, et al.: Minimal recruitment immunotherapy: a retrospective review, Altern Ther Health Med
and activation of dendritic cells within renal cell carcinoma, Clin 5(3):42–47, 1999.
Cancer Res 4(3):585–593, 1998. 120. Alexandroff AB, Jackson AM, O’Donnell MA, James K: BCG immu-
100. Cheng P, Corzo CA, Luetteke N, et al.: Inhibition of den- notherapy of bladder cancer: 20 years on, Lancet 353(9165):1689–
dritic cell differentiation and accumulation of myeloid-derived 1694, 1999.